GAO: FDA’s Monitoring of Early Abortion Drug Does Not Raise Safety Concerns

The Government Accountability Office reviewed the FDA’s relabeling of Mifeprex — an early abortion pill covered by a risk evaluation and mitigation strategy — and concluded that the agency’s monitoring did not raise significant safety concerns.
Source: Drug Industry Daily